Company intelligence / Profile preview
Aramis Biosciences
Boston/Cambridge area*, Massachusetts, United Statesaramisbio.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Aramis Biosciences’ lead candidate, A197—a first-in-class topical immunomodulatory agent—completed a Phase II trial for dry eye disease. The trial investigated efficacy, safety, and tolerability versus vehicle control. The primary endpoint was change from baseline in corneal fluorescein staining at 12 weeks. Following completion of the Phase II study in May 2023, the probability of successful progression to next development stage increased by 10 points to 36% according to GlobalData’s PTSR metric[8]. No commercialized products yet.
- Therapeutic areas
- Ophthalmology
- Modalities
- Large moleculeSmall molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Dompé farmaceutici S.p.A. (licensor of A197 and shareholder)Exscalate/Dompé farmaceutici S.p.A. (computational drug discovery partnership)Safar Partners (lead investor Series A financing)
Beyond the preview
Go deeper on Aramis Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aramis Biosciences.